Knott David M Jr出售了稀有病药公司Catalyst和Biomarin的大量股份。 Knott David M Jr sold significant shares in rare disease drug companies Catalyst and BioMarin.

Knott David M Jr出售了2 000股催化剂制药公司(CPRX),将其持有量减少了0.9%,达到438万美元。 Knott David M Jr sold 2,000 shares of Catalyst Pharmaceuticals (CPRX), reducing his holdings by 0.9% to $4.38 million. 同时,他将BioMarin制药公司(BMRN)的股份减少了82.9%,达到5 800股,价值381 000美元。 Meanwhile, he decreased his BioMarin Pharmaceutical (BMRN) holdings by 82.9% to 5,800 shares, valued at $381,000. Catalyst Pharmaceuticals 专注于罕见病的治疗，而 BioMarin Pharmaceutical 最近超过了收益预期，一致给予“适度买入”评级和 94 美元的目标价。 Catalyst Pharmaceuticals focuses on therapies for rare diseases, while BioMarin Pharmaceutical recently surpassed earnings expectations, with a consensus "Moderate Buy" rating and a $94 price target.